Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory ... Last year, Novartis bought US biotech IFM Tre – a subsidiary of IFM Therapeutics – in a deal worth ...

they obtained their NLRP3 inhibitor product candidate (DFV890), which is in Phase II clinical trials for the treatment of osteoarthritis, through the acquisition of IFM Therapeutics in 2019.

Novartis, meanwhile, bought US biotech IFM Tre – a subsidiary of ... reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate ...

Nico Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease and nonalcoholic fatty liver disease (metabolic dysfunction-associated ...

Researchers from Nanjing University and Peking University presented the discovery and preclinical characterization of novel NLRP3 inhibitors as potential therapeutic candidates for the treatment of ...

including those in which IL-1 antagonism has already been validated as a therapeutic approach.” Pipeline Updates and Anticipated Milestones NLRP3 Inhibitor Portfolio: Ventyx is advancing a ...

US-based biopharmaceutical company Halia Therapeutics has begun a Phase ... HT-6184 is an orally bioavailable inhibitor of the NEK7/NLRP3 inflammasome, which is known to play a significant role ...